Syndax Pharmaceuticals Inc — Director's Dealing 2021

Aug 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-08-18

Reporting Person: Egros Fabrice (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-18	Common Stock	M	15635.00	$7.88	Acquired	31635.00	Direct
2021-08-18	Common Stock	S	15635.00	$15.7549	Disposed	16000.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-18	Stock Options (Right to buy)	$7.88	M	15635.00	Disposed	2029-06-10	Common Stock (0.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 77,682 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $15.58 to $15.94.

F3: This option is fully vested.